AI Article Synopsis

  • The study presents a new nanocomposite (Fe/S-16/ZIF-8) that combines biocompatible metal-organic frameworks (MOFs) and magnetic nanocarriers for enhanced targeted drug delivery and imaging in cancer treatment.
  • Research showed that this composite significantly improves the release of the cancer drug cisplatin (over 75% release) compared to its individual components and exhibits good anticancer activity against various cancer cell lines (like MCF-7 and HeLa).
  • Additionally, the composite demonstrates antibacterial properties, making it a promising multifunctional platform for both cancer therapy and combating drug-resistant infections.

Article Abstract

Nanoformulation involving biocompatible MOFs and magnetic nanocarriers is an emerging multifunctional platform for drug delivery and tumor imaging in targeted cancer therapeutics. In this study, a nanocomposite has been developed comprising Fe/SBA-16 and ZIF-8 (Fe/S-16/ZIF-8) through ultrasonication. The drug delivery of cisplatin was studied using an automated diffusion cell system equipped with a flow type Franz cell. The anticancer activity of Fe/S-16/ZIF-8 was studied in MCF-7, HeLa cells and Human Foreskin Fibroblast (HFF-1) cells. XRD and -spacing measurements of Fe/S-16/ZIF-8 using TEM revealed the presence of cubic-structured FeO, γ-FeO (magnetite), and α-FeOOH (goethite) over an SBA-16/ZIF-8 nanocomposite. The composite showed a surface area of 365 m g, a pore size of 8.3 nm and a pore volume of 0.33 cm g. VSM analysis of Fe/S-16/ZIF-8 showed that it possessed paramagnetic behavior with a saturated magnetization value of 2.39 emu g. The Fe/Fe coordination environment was characterized using diffuse reflectance spectroscopy. The cisplatin drug delivery study clearly showed the synergistic effects present in Fe/S-16/ZIF-8 with over 75% of cisplatin release as compared to that of Fe/S-16 and ZIF-8, which showed 56% and 7.5%, respectively. The morphology analysis of CP/Fe/SBA-16/ZIF-8 using TEM showed an effective transit of nanoparticles into MCF-7 cells. The lethal concentration (LC) of Fe/SBA-16/ZIF-8 for MCF-7 and HeLa cells is 0.119 mg mL and 0.028 mg mL at 24 h, respectively. For HFF-1 cells, the LC is 0.016 mg mL. The antibiofilm activity of Fe/SBA-16/ZIF-8 was investigated against biofilm-forming strains of drug resistant and MRSA by a microtiter tissue culture plate assay. Overall, nanosized ZIF-8 with a bioactive alkaloid imidazole inside the 3D cage type of SBA-16 pores is found to exhibit both anticancer and antibacterial properties. A Fe/S-16/ZIF-8 composite could be effectively used as a drug and drug delivery system against cancer and promote antibacterial activity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092600PMC
http://dx.doi.org/10.1039/c9ra07461aDOI Listing

Publication Analysis

Top Keywords

drug delivery
16
anticancer antibacterial
8
antibacterial properties
8
mcf-7 hela
8
hela cells
8
hff-1 cells
8
drug
6
fe/s-16/zif-8
6
cells
5
cisplatin
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!